Awakn Life Sciences: A Leader in Ketamine-Assisted Therapy Research
Summary
Awakn Life Sciences (CSE: AWKN) is at the forefront of research into ketamine-assisted therapy for alcohol use disorder (AUD). The company has successfully completed a Phase 2 trial and received clinical trial authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) for its Phase 3 trial.
Phase II Trial Results
Awakn's Phase 2 trial demonstrated the efficacy of ketamine-assisted therapy for AUD. The study found that participants achieved an average of 86% abstinence over the six months following treatment.
Phase III Trial
The company's Phase III trial, known as MORE, is exploring the use of ketamine-assisted therapy for severe AUD. The first patient has been screened in, and the trial is expected to provide further evidence of the effectiveness of this treatment.
Benefits of Ketamine-Assisted Therapy
Ketamine-assisted therapy is a promising treatment for AUD due to its rapid onset of action and long-lasting effects. Ketamine, a dissociative anesthetic, has been shown to reduce cravings and improve mood and cognitive function in individuals with AUD.
Safety and Efficacy
Ketamine-assisted therapy has been well-tolerated in clinical trials, with few adverse effects reported. The MHRA's authorization of Awakn's Phase III trial is a testament to the safety and potential efficacy of this treatment.
Conclusion
Awakn Life Sciences is leading the way in research into ketamine-assisted therapy for AUD. Its successful Phase II trial results and ongoing Phase III trial provide strong evidence for the potential of this treatment to revolutionize the way AUD is treated.
Comments